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present,	49	such	Consensus	Documents	appear	in	the	OECD	database	(alongside	12	more	general	
guidance	documents),	with	reports	being	put	together	upon	request.	As	such,	they	need	to	be	broadened	
to	include	many	more	such	organisms—the	compendium	of	case	studies	I	describe	previously	could	fit	in	
very	well	with	this	scheme.		
	
Given	the	OECD’s	work	in	this	area,	another	possible	mechanism	for	the	setting	of	standards	and	best	
practices	for	biosafety	regulation	would	be	to	use	it	as	a	convener	of	a	Global	Regulatory	Forum	for	
synthetic	biology.	Such	a	forum	would	enable	regulators	to	come	together	and	discuss	key	issues,	while	
also	giving	a	voice	to	researchers	and	other	stakeholders.	As	a	venue	for	co-creation	of	best	practice	and	
policy,	it	would	also	provide	a	setting	for	regular	benchmarking	of	regulatory	practices	in	different	
countries,	helping	ensure	that	the	global	legislative	landscape	is	suitably	equipped	to	handle	novel	
technologies,	enabling	them	to	reach	their	full	potential	in	an	appropriate,	safe,	and	responsible	manner.	
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